| Literature DB >> 30344915 |
Rita Meleddu1, Simona Distinto1, Filippo Cottiglia1, Rossella Angius2, Marco Gaspari3, Domenico Taverna3, Claudia Melis1, Andrea Angeli4, Giulia Bianco1, Serenella Deplano1, Benedetta Fois1, Sonia Del Prete5, Clemente Capasso5, Stefano Alcaro6, Francesco Ortuso6, Matilde Yanez7, Claudiu T Supuran4, Elias Maccioni1.
Abstract
A novel series of of 4-[(3-phenyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulfonamides (EMAC10111a-g) was synthesized and assayed toward both human carbonic anhydrase isozymes I, II, IX, and XII and cyclooxygenase isoforms. The majority of these derivatives preferentially inhibit hCA isoforms II and XII and hCOX-2 isozyme, indicating that 2,3,4-trisubstituted 2,3-dihydrothiazoles are a promising scaffold for the inhibition of hCA isozymes and of hCOX-2 enzyme. The nature of the substituent at the dihydrothiazole ring position 4 influenced the activity and selectivity toward both enzyme families. EMAC10111g resulted as the best performing compound toward both enzyme families and exhibited preferential activity toward hCA XII and hCOX-2 isozymes.Entities:
Year: 2018 PMID: 30344915 PMCID: PMC6187410 DOI: 10.1021/acsmedchemlett.8b00352
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345